Trial Profile
Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Methyl aminolevulinate (Primary)
- Indications Basal cell cancer
- Focus Therapeutic Use
- 19 Jan 2013 Status changed from recruiting to completed.
- 09 May 2011 New trial record